BayWa (BYW) H2 2024 earnings summary

Executive summary

• Faced a severe liquidity and debt crisis in 2024, triggering a comprehensive reorganisation and restructuring program.

• Initiated asset sales, cost-cutting, and refinancing measures to restore financial stability and focus on core business segments.

• Major divestments include RWA AG and Cefetra Group, with proceeds used to reduce debt and strengthen liquidity.

• New management and governance structure implemented, with a focus on operational competitiveness and profitability.

• Auditor highlighted material uncertainty regarding going concern, dependent on successful execution of restructuring.

Financial highlights

• Revenues declined 11.7% year-over-year to €21.15 billion, mainly due to weak performance in Renewable Energies, Cefetra, Agri Trade & Service, Energy, and Construction segments.

• Group EBIT fell sharply to minus €1,084.8 million from €304.0 million in the prior year, driven by impairments and weak operating results.

• Net loss for the year was €1,604.1 million, compared to a loss of €93.4 million in 2023.

• EBITDA dropped to minus €162.5 million from €587.3 million, reflecting operational challenges and restructuring costs.

• Equity ratio fell to 0.3% (from 13.7%), with equity at €35.3 million and total assets at €10.85 billion.

• Cash flow from operating activities increased to €941.5 million, mainly due to inventory and receivables reductions.

Outlook and guidance

• Adjusted EBITDA expected to rise sharply in 2025, with first positive effects from reorganisation anticipated.

• Further revenue decline expected due to divestments, but adjusted EBITDA margin targeted to increase from 0.3% in 2024 to over 4% by 2028.

• Segment outlooks: Agri Trade & Service and Agricultural Equipment expect declines in adjusted EBITDA; Heating & Mobility and Building Materials anticipate improvements; Renewable Energies and Global Produce forecast strong EBITDA growth.

• Available liquidity expected to decline in 2025 due to deconsolidation of Cefetra and increased operational liquidity needs.